Denali Stock Analysis

DNLI
 Stock
  

USD 35.19  1.04  2.87%   

The current price rise of Denali Therapeutics could raise concerns from stockholders as the firm is trading at a share price of 35.19 on 456,300 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in September. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.06. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Denali Therapeutics partners.
Continue to Investing Opportunities.
  
The Denali Therapeutics stock analysis report makes it easy to digest most publicly released information about Denali Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Denali Stock analysis module also helps to analyze the Denali Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Denali Stock Analysis Notes

About 16.0% of the company shares are held by company insiders. The book value of Denali Therapeutics was currently reported as 8.3. The company has Price/Earnings (P/E) ratio of 159.36. Denali Therapeutics had not issued any dividends in recent years. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Denali Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 380 people. To learn more about Denali Therapeutics call Ryan Watts at 650 866 8548 or check out https://www.denalitherapeutics.com.

Denali Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Denali Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Denali Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Denali Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 82.88 M. Net Loss for the year was (285.76 M) with loss before overhead, payroll, taxes, and interest of (216.69 M).
Denali Therapeutics currently holds about 957.52 M in cash with (233.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.79.
Over 77.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Denali Therapeutics exotic insider transaction detected

Denali Therapeutics Upcoming and Recent Events

Earnings reports are used by Denali Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Denali Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report2nd of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Denali Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Denali Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Denali Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Denali Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
8th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
5th of July 2022
Regulation FD Disclosure
View
3rd of June 2022
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders
View
5th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
16th of March 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
28th of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition. Entry into a Material Definitive Agreement
View
14th of February 2022
Regulation FD Disclosure. Unclassified Corporate Event
View
10th of February 2022
Financial Statements and Exhibits. Other Events
View

Denali Therapeutics Thematic Classifications

In addition to having Denali Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Denali Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 4.59 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Denali Therapeutics's market, we take the total number of its shares issued and multiply it by Denali Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Denali Profitablity

Denali Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Denali Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Denali Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Denali Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Denali Therapeutics' profitability requires more research than a typical breakdown of Denali Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(28.00) (30.21) 
Return on Average Assets(0.20) (0.21) 
Return on Average Equity(0.28) (0.29) 
Return on Invested Capital(0.29) (0.31) 
Return on Sales(5.98) (6.14) 

Management Efficiency

The entity has return on total asset (ROA) of (12.68) % which means that it has lost $12.68 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (28.25) %, meaning that it created substantial loss on money invested by shareholders. Denali Therapeutics management efficiency ratios could be used to measure how well denali therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -30.21. The current Return on Average Assets is estimated to decrease to -0.21. Denali Therapeutics Total Assets Per Share are most likely to increase slightly in the upcoming years. The last year's value of Total Assets Per Share was reported at 11.48. The current Net Current Assets as percentage of Total Assets is estimated to increase to 37.93, while Total Assets are projected to decrease to roughly 1.2 B.
Last ReportedProjected for 2022
Book Value per Share 7.92  7.46 
Enterprise Value over EBIT(18.00) (18.47) 
Enterprise Value over EBITDA(18.11) (18.59) 
Price to Book Value 5.66  5.89 
Tangible Assets Book Value per Share 11.55  13.67 
Enterprise Value5.1 BB
Tangible Asset Value1.4 B1.2 B

Technical Drivers

As of the 18th of August 2022, Denali Therapeutics shows the Mean Deviation of 3.22, downside deviation of 3.41, and Coefficient Of Variation of 563.67. Denali Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Denali Therapeutics, which can be compared to its rivals. Please confirm Denali Therapeutics jensen alpha, as well as the relationship between the potential upside and skewness to decide if Denali Therapeutics is priced favorably, providing market reflects its regular price of 35.19 per share. Given that Denali Therapeutics has jensen alpha of 0.5891, we urge you to verify Denali Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Denali Therapeutics Price Movement Analysis

The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Triangular Moving Average shows Denali Therapeutics double smoothed mean price over a specified number of previous prices (i.e., averaged twice).
.

Denali Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Denali Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Denali Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Denali Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Denali Therapeutics Predictive Daily Indicators

Denali Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Denali Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Denali Therapeutics Forecast Models

Denali Therapeutics time-series forecasting models is one of many Denali Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Denali Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Denali Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Denali Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Denali shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Denali Therapeutics. By using and applying Denali Stock analysis, traders can create a robust methodology for identifying Denali entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin 16.82  18.15 
EBITDA Margin(5.81) (5.96) 
Gross Margin 0.90  0.89 
Profit Margin(5.97) (6.13) 
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Denali Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 380 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Denali Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Fundamental Analysis Now

   

Fundamental Analysis

View fundamental data based on most recent published financial statements
All  Next Launch Module
Continue to Investing Opportunities. Note that the Denali Therapeutics information on this page should be used as a complementary analysis to other Denali Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Denali Stock analysis

When running Denali Therapeutics price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Is Denali Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.6 B
Quarterly Revenue Growth YOY
1.29
Return On Assets
-0.13
Return On Equity
-0.29
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Denali Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.